UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

  Date of Report (Date of earliest event reported): August 10, 2017

 

 

ENZON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

 

 

Delaware		0-12957		22-2372868
(State or other jurisdiction of		(Commission File Number)		(IRS Employer Identification No.)
incorporation)

 

20 Commerce Drive (Suite 135), Cranford, New Jersey		07016
(Address of principal executive offices)		(Zip Code)

 

(732) 980-4500
(Registrant’s telephone number, including area code)

 

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ 

 

 

 

Item 8.01.

Other Events.

 

On August 10, 2017, the Board of Directors of Enzon Pharmaceuticals, Inc. (the “Company”) declared a special cash dividend of $0.15 per share of the Company’s common stock, payable on September 28, 2017 to stockholders of record as of the close of business on August 30, 2017.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	ENZON PHARMACEUTICALS, INC.
	(Registrant)
Date: August 10, 2017	By:	/s/ Andrew Rackear
	Name: Andrew Rackear Title: Chief Executive Officer and Secretary